Abstract |
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.See related article by Okada et al., p. 5485.
|
Authors | Aaron S Mansfield, Marjorie G Zauderer |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 25
Issue 18
Pg. 5438-5440
(Sep 15 2019)
ISSN: 1557-3265 [Electronic] United States |
PMID | 31315884
(Publication Type: Journal Article, Comment)
|
Copyright | ©2019 American Association for Cancer Research. |
Chemical References |
|
Topics |
- Humans
- Japan
- Lung Neoplasms
- Mesothelioma
- Nivolumab
|